Alx Oncology Holdings (ALXO) Revenue (2019 - 2020)
Alx Oncology Holdings recorded quarterly Revenue of $527000.0 in Q2 2020, down 19.54% quarter-over-quarter from $655000.0 in Q1 2020, and down 59.31% year-over-year from $1.3 million in Q3 2019.
Alx Oncology Holdings' Revenue history runs 2 years deep, the most recent figure standing at $527000.0 for Q2 2020.
- In Q2 2020, Revenue fell 59.31% year-over-year to $527000.0; the TTM figure through Mar 2021 stood at $527000.0 (down 88.07% YoY), while the FY2020 annual figure was $1.2 million, down 75.35% from the prior year.
- Revenue came in at $527000.0 for Q2 2020 at Alx Oncology Holdings, down from $655000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $1.3 million in Q2 2019 to a low of $527000.0 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 527,000.00 |
| Mar 31, 2020 | 655,000.00 |
| Dec 31, 2019 | 1.21 Mn |
| Sep 30, 2019 | 1.26 Mn |
| Jun 30, 2019 | 1.30 Mn |